Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by Teacher Retirement System of Texas

Teacher Retirement System of Texas boosted its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 27.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,383 shares of the company’s stock after purchasing an additional 1,369 shares during the quarter. Teacher Retirement System of Texas’ holdings in Krystal Biotech were worth $1,000,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech during the third quarter worth about $40,000. Avanza Fonder AB acquired a new stake in Krystal Biotech during the fourth quarter worth approximately $119,000. KBC Group NV grew its stake in Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company’s stock worth $147,000 after acquiring an additional 297 shares during the period. Blue Trust Inc. raised its holdings in Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock valued at $159,000 after acquiring an additional 433 shares during the last quarter. Finally, US Bancorp DE lifted its stake in shares of Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after purchasing an additional 82 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on KRYS shares. Jefferies Financial Group began coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target for the company. Citigroup boosted their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. HC Wainwright restated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Friday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, Chardan Capital lifted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $220.00.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $183.92 on Friday. The company has a market cap of $5.30 billion, a P/E ratio of 61.51 and a beta of 0.87. Krystal Biotech, Inc. has a one year low of $141.72 and a one year high of $219.34. The business’s 50-day simple moving average is $170.82 and its 200 day simple moving average is $173.73.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business’s revenue for the quarter was up 116.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.30 earnings per share. Analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).